Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin
N A Terrault, S Zhou, C Combs, J A Hahn, J R Lake, J P Roberts, N L Ascher, T L Wright – 1 December 1996 – Prophylactic hepatitis B immunoglobulin (HBIg) reduces the risk of reinfection in hepatitis B surface antigen (HBsAg)‐positive liver transplant recipients. In the medical center of this study, high‐dose HBIg immunoprophylaxis is administered at a fixed dose of 10,000 IU monthly, and in this study, the long‐term efficacy of this treatment regimen was examined.